Genomic Health, Inc. is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. The Oncotype DX® breast cancer test for DCIS predicts the likelihood of recurrence in ductal carcinoma in situ. Please visit www.OncotypeDX.com